Jazz Pharmaceuticals (JAZZ) Competitors

Royalty Pharma (NASDAQ:RPRX) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both finance companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, community ranking, profitability, earnings, institutional ownership and risk.

Do analysts rate RPRX or JAZZ?

Royalty Pharma currently has a consensus target price of $41.60, indicating a potential upside of 23.22%. Jazz Pharmaceuticals has a consensus target price of $187.71, indicating a potential upside of 38.79%. Given Jazz Pharmaceuticals' higher probable upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93

Does the MarketBeat Community prefer RPRX or JAZZ?

Jazz Pharmaceuticals received 812 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 80.85% of users gave Jazz Pharmaceuticals an outperform vote while only 67.92% of users gave Royalty Pharma an outperform vote.

Company	Underperform	Outperform
Royalty Pharma	Outperform Votes 324 67.92%	Underperform Votes 153 32.08%
Jazz Pharmaceuticals	Outperform Votes 1136 80.85%	Underperform Votes 269 19.15%

Does the media prefer RPRX or JAZZ?

In the previous week, Jazz Pharmaceuticals had 8 more articles in the media than Royalty Pharma. MarketBeat recorded 17 mentions for Jazz Pharmaceuticals and 9 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.69 beat Jazz Pharmaceuticals' score of 1.04 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Jazz Pharmaceuticals	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, RPRX or JAZZ?

Royalty Pharma has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500.

Do insiders & institutionals believe in RPRX or JAZZ?

54.3% of Royalty Pharma shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 18.9% of Royalty Pharma shares are held by insiders. Comparatively, 4.2% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Is RPRX or JAZZ more profitable?

Royalty Pharma has a net margin of 37.94% compared to Jazz Pharmaceuticals' net margin of 11.60%. Jazz Pharmaceuticals' return on equity of 29.30% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	37.94%	24.40%	14.01%
Jazz Pharmaceuticals	11.60%	29.30%	9.72%

Which has preferable valuation & earnings, RPRX or JAZZ?

Royalty Pharma has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.26B	8.60	$858.98M	$1.45	23.28
Jazz Pharmaceuticals	$4.07B	2.02	$414.83M	$8.79	15.39

Summary

Royalty Pharma beats Jazz Pharmaceuticals on 10 of the 19 factors compared between the two stocks.